Feed MDGL
MD

Madrigal Pharmaceuticals

MDGL · NASDAQ

$516.56 -0.18% (-$0.94)
1M -3.22%
Market Cap $11.9B
P/E Ratio -
Div. Yield -
ROE 56.65%

Bulios Fair Price

$579.39

12.2% upside

Trenutna cena

$516.56

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica MDGL trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/B 22.64x
P/S 9.24x
EV/EBITDA N/A
Growth
100 /100
Growing
Book val. growth 45.07%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak
Net margin 25.32%
Op. margin 25.13%
FCF margin 16.07%
Quality
13 /100
Poor
ROE 56.65%
ROA 26.12%
Asset turnover 1.03x
Debt
56 /100
Moderate
Current ratio 3.20x
Int. coverage -19.19x
Debt/Equity 0.66x
Stability
46 /100
Moderate
EPS volatility 31.41%
Profitable years 0
Beta -0.99x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o MDGL
Online

O podjetju

Madrigal Pharmaceuticals, Inc. is an American biotechnology company focused on developing new therapeutic drugs for liver and cardiometabolic diseases. The company specializes in research and development of drugs aimed at improving liver health, particularly in relation to non-alcoholic steatohepatitis (NASH) and cirrhosis. Madrigal Pharmaceuticals is known for its innovative technology targeting selective activation of liver receptors, which has the potential to provide effective therapeutic options for patients suffering from these complex and difficult-to-treat conditions.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

William J. Sibold

Employees

915

Headquarters

West Conshohocken

Prihajajoči dogodki

03 NOV.

Earnings

Upcoming earnings report

37d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.